Skip to main content
Signal8

Lo Andrew

SEC insider (Form 3/4/5 filer). CIK 0001679076. Director at BridgeBio Pharma, Inc. (BBIO) and 1 other issuer. 8 reported Form 4/5 transactions since Sep 2024; latest on Jun 22, 2026. Located in PALO ALTO, CA.

Companies Lo Andrew has filed insider reports for

  • BridgeBio Pharma, Inc. (BBIO): Director
  • AbCellera Biologics Inc. (ABCL): Director
Lo Andrew profile photo

Lo Andrew

CIK: 0001679076

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (62.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BridgeBio Pharma, Inc. logo
BBIO

BridgeBio Pharma, Inc.

Director
AbCellera Biologics Inc. logo
ABCL

AbCellera Biologics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

  • BridgeBio Pharma, Inc. logo
    BBIO

    BridgeBio Pharma, Inc.

    Jun 22, 2026
    Award
    Direct
    4K shares-
  • BridgeBio Pharma, Inc. logo
    BBIO

    BridgeBio Pharma, Inc.

    Nov 18, 2025
    Sale
    Indirect
    24K shares at avg. $65.23$1.6M
  • BridgeBio Pharma, Inc. logo
    BBIO

    BridgeBio Pharma, Inc.

    Nov 18, 2025
    Sale
    Indirect
    31K shares at avg. $66.05$2.0M
  • BridgeBio Pharma, Inc. logo
    BBIO

    BridgeBio Pharma, Inc.

    Nov 17, 2025
    Sale
    Direct
    36.8K shares at avg. $66.63$2.5M
  • BridgeBio Pharma, Inc. logo
    BBIO

    BridgeBio Pharma, Inc.

    Nov 17, 2025
    Sale
    Direct
    3.8K shares at avg. $67.06$255K
  • BridgeBio Pharma, Inc. logo
    BBIO

    BridgeBio Pharma, Inc.

    Jun 20, 2025
    Award
    Direct
    6.6K shares-
  • AbCellera Biologics Inc. logo
    ABCL

    AbCellera Biologics Inc.

    Jun 12, 2025
    Award

    Share option (right to buy)

    Direct
    238.9K shares-
  • BridgeBio Pharma, Inc. logo
    BBIO

    BridgeBio Pharma, Inc.

    May 2, 2025
    Sale
    Indirect
    100K shares at avg. $38.50$3.8M

1-8 of 8